Cargando…
Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes
β-Lactam antibiotics are presently the most important treatments for infections by pathogenic Escherichia coli, but their use is increasingly compromised by β-lactamases, including the chromosomally encoded class C AmpC serine-β-lactamases (SBLs). The diazabicyclooctane (DBO) avibactam is a potent A...
Autores principales: | Lang, Pauline A., Leissing, Thomas M., Page, Malcolm G. P., Schofield, Christopher J., Brem, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849013/ https://www.ncbi.nlm.nih.gov/pubmed/33199391 http://dx.doi.org/10.1128/AAC.02073-20 |
Ejemplares similares
-
Molecular Basis of Class A β-Lactamase Inhibition by Relebactam
por: Tooke, Catherine L., et al.
Publicado: (2019) -
Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli
por: Lang, Pauline A., et al.
Publicado: (2020) -
Interaction of Avibactam with Class B Metallo-β-Lactamases
por: Abboud, Martine I., et al.
Publicado: (2016) -
Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers
por: Brem, Jürgen, et al.
Publicado: (2015) -
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
por: Deroche, Luc, et al.
Publicado: (2023)